• SpyGlass Pharma bought Advanced Vision Science from Santen for about USD 13 million in cash, taking 100% of the shares.
• The deal secures commercial-scale manufacturing capacity for intraocular lenses used in the Phase 3 BIM-IOL System trials.
• AVS will remain the exclusive supplier of several IOL types to Santen for commercialization in Japan.
• Ongoing licensing includes AVS’s hydrophobic acrylic lens material for Bausch + Lomb’s enVista IOL line.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010800PRIMZONEFULLFEED9837595) on October 01, 2026, and is solely responsible for the information contained therein.